Soft Gelatin Capsule Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Soft gelatin capsule plant sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹5.0 crore - ₹88 crore CapEx this DPR captures:

• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
• CDSCO + State Drug Controller dual approval for new formulations
• WHO-GMP and Schedule M revised standards compliance
• Plant Master File (PMF) and Site Master File (SMF) for export dossier

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The soft gelatin capsule market in India operates across multiple high-growth verticals. The pharmaceutical formulations segment remains the primary driver, supported by the need to encapsulate poorly water-soluble compounds and lipid-based formulations to enhance bioavailability and patient compliance. The nutraceutical segment is experiencing explosive growth, with India's nutraceutical market projected to grow at a CAGR exceeding 15%, representing a major demand catalyst for SGC production capacity.</p><p>Distribution channels are undergoing a structural shift.

Traditional retail pharmacies and brick-and-mortar chemist networks continue to hold the largest market share due to established consumer trust. However, online retail and e-commerce platforms represent the fastest-growing distribution channel, reflecting broader digitization of healthcare consumption in India. The sector also presents substantial export potential, with over 401 recorded export shipments of soft gelatin capsule products and processing streams versus 48 recorded import entries for related equipment and formulations, with 8 suppliers or exporters and 89 buyers tracked across core database metrics.</p><p>The domestic SGC and CDMO industry is highly fragmented, exhibiting a dual structure of a limited organized tier and a vast unorganized local player base.

Organized and semi-organized manufacturing plants are concentrated primarily in Himachal Pradesh, Rajasthan, and Gujarat, with mid-scale contract manufacturing plants in Himachal Pradesh and Rajasthan maintaining production capacity standards aligned with national regulatory benchmarks. Market valuation figures show 2022 at USD 375.3 million, 2024 between USD 346.43 million and USD 349.8 million, 2025 between USD 371.82 million and USD 4.2 billion depending on metrics, 2030 at USD 685.6 million, and 2035 at USD 754.24 million, with the CAGR ranging from 7.33% to 7.8%.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

<p>The technology landscape for soft gelatin capsule manufacturing has evolved significantly, with automation and robotics now defining competitive operations. As of 2026, over 70% of new softgel plant installations incorporate robotic handling systems, boosting production efficiency by approximately 45%. High-speed automated encapsulation lines operate at speeds that substantially outpace manual operations, with industrial and commercial softgel encapsulation units priced between INR 26,00,000 and INR 45,00,000 representing the mid-tier of available machinery.

Key machinery manufacturers in India include MOI Engineering Private Limited, Lodha International LLP, and Riddhi Pharma Machinery Ltd.</p><p>Energy efficiency has become a critical operational parameter. Upgraded energy-efficient softgel drying systems lower operational energy consumption by 28%, and energy-efficient components integrated by equipment manufacturers reduce overall power usage by up to 25%. These efficiency improvements directly affect operational economics given the energy-intensive nature of the drying phase in softgel manufacturing.</p><p>A major technological frontier is the development of plant-based and vegan softgel alternatives to traditional gelatin capsules.

Carrageenan-modified starch (CMS), introduced commercially around 2001, represents the foundational blend using red and brown seaweed extracts combined with modified starches. Modified tapioca starch derived from cassava root enables carrageenan-free vegan softgels marketed under names such as Plantsgels. Pea starch and other plant-derived formulations are also emerging as substitutes.

The animal-based gelatin segment currently commands a 78.36% segment share, but the plant-based alternative segment is gaining momentum driven by consumer preference shifts toward vegan and vegetarian pharmaceutical and nutraceutical products.</p><p>Raw material formulation science for standard soft gelatin capsule shells consists of 40% to 45% gelatin, 8% to 15% water, and 20% to 30% plasticizers such as glycerin or sorbitol. Pharmaceutical and edible grade gelatin raw material is priced between USD 3.00 and USD 8.00 per kilogram, or between USD 3,000 and USD 5,000 per metric ton. Raw material costs represent 30% to 50% of total COGS for softgel and supplement manufacturing, while packaging accounts for 15% to 25% of COGS and manufacturing labor represents 20% to 30%, making raw material sourcing efficiency a primary determinant of plant profitability.</p>

For a Soft Gelatin Capsule Plant within the ₹5-88 crore CapEx range, KAMRIT recommends a blended financing structure with 60-70 percent debt and 30-40 percent equity for mid-scale projects below ₹20 crore, shifting to 50-60 percent debt for larger installations above ₹50 crore. Working capital cycle of 75-90 days should be factored, comprising 25-35 days raw material inventory (gelatin, API, excipients), 15-20 days WIP at encapsulation and drying stages, and 35-45 days finished goods plus receivables.

Primary lending partners for this sector include SIDBI, which offers dedicated pharma MSME schemes with 25 basis point interest concessions under its Cluster Development Programme, and IDBI Bank with pharmaceutical sector-specific lending desks. State bank lenders including SBI and Bank of Baroda provide priority sector lending classification for pharma manufacturing, typically pricing at repo + 2.0-2.5 percent. Private sector banks HDFC, ICICI, and Axis offer faster processing timelines of 45-60 days versus 90-120 days for PSU banks, with interest rates of 9.5-11.5 percent depending on credit profile.

CGTMSE coverage reduces lender risk for projects below ₹10 crore, enabling 80-85 percent loan-to-value ratios. PMEGP funding through KVIC is applicable for smaller facilities, while PLI incentives for bulk drug and medical device manufacturing may extend to formulations with qualifying API synthesis components. Export-oriented units can access ECGC cover and EXIM Bank pre-shipment credit at concessionary rates, critical for facilities targeting US generics export volumes. State incentives in Gujarat (SDIS), Maharashtra (MahaID), and Tamil Nadu (TIDCO) provide capital subsidies of 15-30 percent for greenfield pharma manufacturing in designated industrial zones.

<p>Raw material price volatility poses the most significant operational risk to SGC plant profitability. Gelatin prices have faced continuous upward pressure driven by pork supply constraints and broader commodity dynamics, with ChemAnalyst highlighting this trend as of July 2025. Since raw material costs constitute 30% to 50% of total COGS, any sustained price escalation directly compresses operating margins.

Pharmaceutical and edible grade gelatin pricing between USD 3.00 and USD 8.00 per kilogram means cost exposure can vary by as much as 166% depending on grade sourcing and market timing.</p><p>Supply chain constraints add a secondary layer of risk. The industry relies on specialized inputs including gelatin, plasticizers such as glycerin and sorbitol, and capsule shell manufacturing equipment. With only 8 tracked suppliers or exporters and 89 buyers in core database metrics, supply concentration and limited vendor diversification can create bottlenecks during periods of peak demand or global supply disruption.</p><p>Regulatory compliance burden represents an ongoing cost and operational risk factor.

Operating under the Drugs and Cosmetics Act 1940, Schedule M requirements, FSSAI standards for nutraceutical products, and adherence to the Indian Pharmacopoeia Commission standards requires dedicated quality assurance infrastructure, including full-time quality control chemists, microbiologists, and R&D specialists. Non-compliance can result in production shutdowns, license revocation, or market access restrictions, making the regulatory overhead a material factor in total cost of operation.</p><p>The industry's heavy reliance on animal-based gelatin at 78.36% segment share creates vulnerability to shifts toward plant-based alternatives. While this transition is gradual, manufacturers with investments exclusively in gelatin-based production capacity face asset stranding risk if consumer preference pivots faster than anticipated toward carrageenan-modified starch, modified tapioca starch, pea starch, and emerging vegan formulations.</p><p>Market valuation discrepancy across reporting sources, with 2024 figures ranging from USD 346.43 million to USD 349.8 million and 2025 ranging from USD 371.82 million to USD 4.2 billion, indicates measurement methodology inconsistencies that complicate investment planning and benchmarking.

Energy consumption, while improved by 25% to 28% through efficiency upgrades, remains a significant operational cost factor for drying-intensive softgel manufacturing processes, particularly for operators without access to the latest energy-efficient equipment.</p>